Lovisa Backemar Ph.D

Principal

Stephan Christgau

Managing Partner

Gökçe Günaydin

Investment Associate

5 past transactions

Pretzel Therapeutics

Series A in 2022
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Synklino

Series A in 2022
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.

Cinclus Pharma

Venture Round in 2022
Cinclus Pharma is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland.

Scenic Biotech

Series A in 2022
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.

Synklino

Seed Round in 2020
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.